Description
Pazopanib (GW786034B; GlaxoSmithKline) is a novel multi-targeted, orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 with IC50 values of 10, 30, and 47 nM.
In vitro
Pazopanib (GW786034B; GlaxoSmithKline) is a novel multi-targeted, orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor 1, VEGF receptor 2, and VEGF receptor 3 with IC50 values of 10 nM, 30 nM, and 47 nM. Pazopanib (GW786034B; GlaxoSmithKline) also shows inhibition to platelet-derived growth factor receptor (including PDGFR-alpha and PDGFR-beta), and c-kit, FGF-R1, and c-fms with IC50 of 84, 74, 140, and 146 nM. Pazopanib can inhibit MM cell growth, survival, and migration. It can inhibit MM cell lines including dexamethasone-sensitive MM.1S, dexamethasone resistant MM.1R, doxorubicin (Dox)-sensitive RPMI, Dox-resistant RPMI (Dox40), IL-6-dependent INA-6, OPM2, and U266. Pazopanib suppresses VEGF-Induced Endothelial Cell Proliferation and Migration.
Download Datasheet